Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ammar Muhammad

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Pituitary|August 29, 2016
Pregnancy and acromegalyAmmar Muhammad, Sebastian J Neggers, Aart J van der Lely
Neuroendocrinology|March 21, 2015
Pegvisomant Treatment in AcromegalySebastian J C M M Neggers, Ammar Muhammad, Aart Jan van der Lely
European Journal of Endocrinology|April 3, 2020
Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegalyAart J van der Lely, Emmanuelle Kuhn, Ammar Muhammad, et al.
The Journal of Clinical Endocrinology and Metabolism|April 13, 2017
The Acylated/Unacylated Ghrelin Ratio Is Similar in Patients With Acromegaly During Different Treatment RegimensAmmar Muhammad, Patric J D Delhanty, Martin Huisman, et al.
The Journal of Clinical Endocrinology and Metabolism|January 5, 2019
How to Position Pasireotide LAR Treatment in AcromegalyEva C Coopmans, Ammar Muhammad, Aart J van der Lely, et al.
RSC Advances|December 9, 2024
<i>In situ</i> analysis of heavy metals and halogenated compounds in reclaimed water using novel electrospray ionization combined with plasma ionization linear ion trap mass spectrometryNazifi Sani Shuaibu, Gaosheng Zhao, Fengjian Chu, et al.
The Journal of Clinical Endocrinology and Metabolism|October 23, 2018
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 ExpressionAmmar Muhammad, Eva C Coopmans, Federico Gatto, et al.
The Journal of Clinical Endocrinology and Metabolism|November 21, 2017
Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)Ammar Muhammad, Aart J van der Lely, Patric J D Delhanty, et al.
European Journal of Endocrinology|May 7, 2020
T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegalyEva C Coopmans, Joppe J Schneiders, Nour El-Sayed, et al.
European Journal of Endocrinology|August 5, 2018
Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension studyAmmar Muhammad, Eva C Coopmans, Patric J D Delhanty, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Pituitary|August 29, 2016
Pregnancy and acromegalyAmmar Muhammad, Sebastian J Neggers, Aart J van der Lely
Neuroendocrinology|March 21, 2015
Pegvisomant Treatment in AcromegalySebastian J C M M Neggers, Ammar Muhammad, Aart Jan van der Lely
European Journal of Endocrinology|April 3, 2020
Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegalyAart J van der Lely, Emmanuelle Kuhn, Ammar Muhammad, et al.
The Journal of Clinical Endocrinology and Metabolism|April 13, 2017
The Acylated/Unacylated Ghrelin Ratio Is Similar in Patients With Acromegaly During Different Treatment RegimensAmmar Muhammad, Patric J D Delhanty, Martin Huisman, et al.
The Journal of Clinical Endocrinology and Metabolism|January 5, 2019
How to Position Pasireotide LAR Treatment in AcromegalyEva C Coopmans, Ammar Muhammad, Aart J van der Lely, et al.
RSC Advances|December 9, 2024
<i>In situ</i> analysis of heavy metals and halogenated compounds in reclaimed water using novel electrospray ionization combined with plasma ionization linear ion trap mass spectrometryNazifi Sani Shuaibu, Gaosheng Zhao, Fengjian Chu, et al.
The Journal of Clinical Endocrinology and Metabolism|October 23, 2018
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 ExpressionAmmar Muhammad, Eva C Coopmans, Federico Gatto, et al.
The Journal of Clinical Endocrinology and Metabolism|November 21, 2017
Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)Ammar Muhammad, Aart J van der Lely, Patric J D Delhanty, et al.
European Journal of Endocrinology|May 7, 2020
T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegalyEva C Coopmans, Joppe J Schneiders, Nour El-Sayed, et al.
European Journal of Endocrinology|August 5, 2018
Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension studyAmmar Muhammad, Eva C Coopmans, Patric J D Delhanty, et al.
Pageof 2